Skye Bioscience, Inc. — Director's Dealing 2021

Dec 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Skye Bioscience, Inc. (SKYE)
CIK: 0001516551
Period of Report: 2021-12-14

Reporting Person: Ward Keith Wayne (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-14	Director Option Grant (Right to Buy)	$0.058	A	250000	Acquired	2031-12-14	Common Stock (250000.0)	Direct

Footnotes

F1: The Option grant shall be exercisable for a price of $0.058 per Option Share for ten years from December 14, 2021 (the "Grant Date") and the Options will vest in equal monthly installments over the one year period from the Grant Date.